Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GlaxoSmithKline 2009 Share Value Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity award transactions and share pricing.
- Ordinary Share Price (Aug 27, 2013): £16.77
- ADS Price (Aug 27, 2013): $51.76
Material Changes
The filing details specific changes in shareholdings for connected persons of Directors and PDMRs resulting from awards made on August 27, 2013:
- Mr. P. Thomson / Mrs. K. Thomson: Award of 2,076 Ordinary Shares.
- Dr. M. Slaoui (Executive Director) / Dr. K. Slaoui: Award of 2,990 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider transactions compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the total number of shares and ADSs awarded to the specific connected persons listed.
- Confirm the closing middle market prices used for valuation on August 27, 2013.
- Review the GlaxoSmithKline 2009 Share Value Plan terms to understand the vesting conditions for these awards.